Diaclone
Diaclone has been acquired by Medix Biochemica
Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of Diaclone from Biotech Investissement Group. As a result of the acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its local presence in Western Europe. Diaclone will become an important part of the Immunodiagnostic Reagents Business Unit within Medix Biochemica’s group structure, and its high-quality operations will continue in Besançon, France.
Medix Biochemica
DDA & Company - Paris, FRANCE
DDA & Company is an international corporate finance boutique with a presence in the US and Europe. We focus on a selection of advisory services including: * Mergers & Acquisitions * Strategic and Corporate Finance Advisory * Investment Management Outsourcing We have built a reputation as a first-rate M&A specialist targeting small and mid-cap companies, with a particularly strong expertise in structuring and negotiating cross-border deals. Our clients are entrepreneurs, investment funds or large international corporations, which we assist on the whole coporate finance value chain.
+33 1 55 04 80 47
awimbush@ddacompany.fr
http://www.ddacompany.com/en/home/
